Graft-versus-host disease in lung transplantation: 4 Case reports and literature review

Journal of Heart and Lung Transplantation

Volumn 22, Issue 6, 2003, Pages 691-697

  Luckraz, Heyman ^a   Zagolin, Monica ^a   McNeil, Keith ^a   Wallwork, John ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALEMTUZUMAB; ALKALINE PHOSPHATASE; AZATHIOPRINE; BASILIXIMAB; BILIRUBIN; COTRIMOXAZOLE; CYCLOSPORIN; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ANEMIA; ARTICLE; BONE MARROW APLASIA; CASE REPORT; CELL TRANSFER; CHIMERA; DIARRHEA; ERYTHRODERMA; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEART LUNG TRANSPLANTATION; HUMAN; HYPERBILIRUBINEMIA; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE COUNT; LEUKOPENIA; LITERATURE; LUNG FIBROSIS; LUNG TRANSPLANTATION; LYMPHOID CELL; LYMPHOID TISSUE; MALE; PRIORITY JOURNAL; PROPHYLAXIS; PROTHROMBIN TIME; PRURITUS; RASH; SARCOIDOSIS; SKIN BIOPSY; THROMBOCYTOPENIA;

EID: 0038799776     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(02)00811-2     Document Type: Article

References (35)

1. Billingham R.E. A simple method for inducing tolerance of skin homografts in mice. Transplant Bull. 4:1957;67-71.
2. Barnes D.W.H., Loutit J.F. Spleen protection the cellular hypothesis . Bacq Z.M. Radiobiology symposium. 1955;134-145 Butterworth, London.
3. Flowers M.E.D., Kansu E., Sullivan K.M. Pathophysiology and treatment of graft-versus-host disease. Hemat Stem Cell Ther. 13:(5):1999;1091-1112.
4. Ferrara J.L.M., Deeg H.J. Graft versus host disease. N Engl J Med. 324:(10):1991;667-674.
5. Pfitzmann R., Hummel M., Grauhan O., Waurick P., Ewerta R., Loebe M., Weng Y., Hetzer R. Acute graft-versus-host disease after human heart-lung transplantation a case report . J Thorac Cardiovasc Surg. 114:(2):1997;285-287.
6. M-Chau E.M., Lee K., Yew W.W., Chiu C.S., Wang E.P. Mediastinal irradiation for graft-versus-host disease in a heart-lung transplant recipient. J Heart Lung Transplant. 16:(9):1997;974-979.
7. Billingham R.E. The biology of graft-versus-host reactions. Harvey Lectures. 62:1966;21-78.
8. Goulmy E., Schipper R., Pool J., Blokland E., Falkenburg J.H., Vossen J., Grathwohl A., Vogelsang G.B., van Houwelingen H.C., van Rood J.J. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med. 334:1996;281-285.
9. Martin P.J. How much benefit can be expected from matching from minor antigens in allogeneic marrow transplantation? Bone Marrow Transplant. 20:1997;97-100.
10. Nash R.A., Pepe M.S., Storb R., Longton G., Pettinger M., Anasetti C., Appelbaum F.R., Bowden R.A., Deeg H.J., Doney K. Acute graft-versus-host disease analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate . Blood. 80:1992;1838-1845.
11. Petersdorf E.W., Longton G.M., Anasetti C., Martin P.J., Mickelson E.M., Smith A.G., Hansen J.A. The significance of HLA-DR matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood. 86:1995;1606-1613.
12. Weisdorf D.J., Snover D.C., Haake R., Miller W.J., McGlave P.B., Blazar B., Ramsay N.K., Kersey J.H., Filipovich A. Acute upper gastrointestinal graft-versus-host disease clinical significance and response to immunosuppressive therapy . Blood. 76:(3):1990;624-629.
13. Deeg H.K., Kingeman H.G., Phillips G.L., et al. A guide to blood and marrow transplantation. 3rd ed:1999;Springer, Heidelberg.
14. Sullivan K. Acute and chronic graft-versus-host disease. Int J Cell Cloning. 4:1986;42-45.
15. Morris S.C., Cheek R.L., Cohen P.L., Eisenberg R.A. Allotype-specific immunoregulation of autoantibody production by host B cells in chronic graft-versus-host disease. J Immunol. 144:(3):1990;916-922.
16. Sullivan K.M., Witherspoon R.P., Storb R., Wieden P., Flournoy N., Pahlberg S., Deeg H.J., Sanders J.E., Doney K.C., Appalboun F.R. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-versus-host disease prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation . Blood. 72:1988;546-554.
17. Kernan N.A., Collins N.H., Juliano L., Cartagena T., Dupont B., O'Reilly R.J. Clonable T lymphocytes in T cell-depleted bone marrow transplant correlated with development of graft-v-host disease. Blood. 68:1986;770-776.
18. Przepiorka D., Weisdorf D., Martin P., Klingemann H.G., Beatty P., Hows J., Thomas E.D. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 15:1995;825-828.
19. Darmstat G., Donnenbeg A.D., Vogelsang G.B. Clinical, laboratory and histopathologic indicators of the development of progressive acute graft-versus-host disease. J Invest Dermatol. 99:(4):1992;397-402.
20. McDonald G.B., Shulman H.M., Sullivan K.M., Spencer G.D. Intestinal and hepatic complications of human bone marrow transplantation. Gastroenterology. 90:1986;770-784.
21. Hess A.D., Fischer A.C. Immune mechanisms in cyclosporin-induced syngeneic graft-versus-host disease. Transplantation. 48:1989;595-600.
22. Anderson K.C., Weinstein H.J. Transfusion-associated graft-versus-host disease. N Engl J Med. 323:1990;315-321.
23. Nash R.A., Antin J., Karanes C., Fay J.W., Avalos B.R., Yeager A.M., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporin for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 96:(6):2000;2062-2068.
24. Wagner J.E., Santos G.W., Noga S.J., Rowley S.D., Davis J., Vogelsang G.B., et al. Bone marrow graft engineering by counterflow centrifugal elutriation results of a phase I-II clinical trial . Blood. 75:1990;1370-1377.
25. Antin J.H., Bierer B.E., Smith B.R., Ferrara J., Guinan E.C., Sieff C., et al. Selective depletion of bone marrow T lymphocytes with ante-CD5 monoclonal antibodies effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies . Blood. 78:1991;2139-2149.
26. Almani W.Y., Lipman M.L., Stevens A.C., Zanker B., Hadro E.T., Strom T.B. Abrogation of glucomediated inhibition of T cell proliferation by the synergistic action of IL-2, IL6 and IFN-gamma. J Immunol. 146:(10):1991;3523-3527.
27. Van Lint M.T., Uderzo C., Locasciulli A., Magolino I., Schine R., Locatelli F., et al. Early treatment of acute-versus-host disease with high or low-dose 6-methylprednisolone a multicenter randomised trial from the Italian Group for Bone Marrow Transplantation . Blood. 92:1998;2288-2293.
28. Martin P.J., Schoch G., Fisher L., Byers V., Anasetti C., Appelbaum F.R., et al. A retrospective analysis of therapy for acute graft-versus-host disease initial treatment . Blood. 76:1990;1464-1472.
29. Deeg H.K., Henslee Downee P.J. Management of acute graft versus host disease. Bone Marrow Transplant. 6:1990;1-8.
30. Tse J.C., Moore T.B. Monoclonal antibodies in the treatment of steroid-resistant graft-versus-host disease. Pharmacotherapy. 18:1998;988-1000.
31. Herve P., Bordigoni P., Cahn J.Y., Flesch M., Tiberghien P., Rocadot E., et al. Use of monoclonal antibodies in vivo as a therapeutic strategy for acute GVHD in matched and in bone marrow transplantation. Transplant Proc. 23:1991;1692-1694.
32. Herve P., Wijdenes J., Bergerat J.P., Bordigoni P., Milpied N., Cahn J.Y., et al. Treatment of corticosteroid resistant graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody. Blood. 75:(4):1990;1017-1023.
33. Przepiorka D., Kernan N.A., Ippoliti C. Daclizumab, a humanized anti-interleukin 2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood. 95:2000;83.
34. Cahn J.Y., Bordigoni P.K., Tiberghien P., Milpied N., Brion A., Widjenes J., et al. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporin with or without an anti interleukin-2 receptor monoclonal antibody. A multicenter phase III study. Transplantation. 60:1995;929-942.
35. Sykes M., Romick M.L., Hoyes K.A., Sachs D.H. In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus host disease and permits alloengraftment. J Exp Med. 171:1990;645-658.